Hepatitis C Virus

Positive interim results of phase IB trial of isatoribine reported

Published in Hepatitis Weekly, December 29th, 2003

Anadys Pharmaceuticals, Inc., reported at the 10th International Meeting on Hepatitis C and Related Viruses in Kyoto, Japan, that interim results from an ongoing clinical trial of isatoribine (ANA245) demonstrate that the drug is safe and well-tolerated.

Although efficacy is not a stated objective of the phase IB clinical trial and the number of patients was small, results showed that isatoribine is biologically active in adults with chronic hepatitis C virus (HCV) infection.

Isatoribine, which is believed to act by a mechanism of action involving interaction with Toll-like receptor 7 (TLR7) and stimulate the patient's own immune system, is one of a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2003-12-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry